Cargando…

2266. Management of Ertapenem-Resistant, Meropenem-Susceptible Enterobacteriaceae

BACKGROUND: Carbapenemases are the most frequent mechanism of carbapenem resistance in Enterobacteriaceae. However, alternative mechanisms such as loss of porin channels or up-regulation of efflux pumps can cause intermediate- to high-level resistance to ertapenem (ERTA) and possibly reduced suscept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srinivas, Pavithra, Wu, Janet, Neuner, Elizabeth A, Pallotta, Andrea, Richter, Sandra S, Tsigrelis, Constantine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810591/ http://dx.doi.org/10.1093/ofid/ofz360.1944

Ejemplares similares

150. Low Propensity for Development of Spontaneous In Vitro Resistance to Tebipenem, Ertapenem and Meropenem Among Enterobacterales Uropathogens
por: VanScoy, Brian D, et al.
Publicado: (2022)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study
por: Teo, Jocelyn, et al.
Publicado: (2012)

Evaluating the Impact of Long-Term Outpatient Ertapenem (ETP) vs. Ceftriaxone (CTX) on Clinical Success and Development of Resistance for Documented Enterobacteriaceae Infections
por: Carver, Peggy, et al.
Publicado: (2017)

2068. Evaluation of Ceftazidime-Avibactam Disks from Different Commercial Manufacturers for Susceptibility Testing against Meropenem Nonsusceptible Enterobacteriaceae
por: Lin, Lynn-Yao, et al.
Publicado: (2018)

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

2447. Ertapenem and Faropenem for the Treatment of Drug-Resistant Tuberculosis
por: Satta, Giovanni, et al.
Publicado: (2018)

Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales
por: Zhang, Jingjia, et al.
Publicado: (2021)

2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019)

1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
por: Chou, Andrew, et al.
Publicado: (2018)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
por: Ackley, Renee, et al.
Publicado: (2019)

Efficacy and Cost Comparison of Ertapenem as Outpatient Parenteral Antimicrobial Therapy in Acute Pyelonephritis due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae
por: Ramasubramanian, V., et al.
Publicado: (2018)

1097. An Antimicrobial Stewardship Intervention to Optimize Cefazolin Dosing for Surgical Prophylaxis
por: Neuner, Elizabeth A, et al.
Publicado: (2019)

Screening for Carbapenemases in Ertapenem-Resistant Enterobacteriaceae Collected at a Tunisian Hospital Between 2014 and 2018
por: Kollenda, Hans, et al.
Publicado: (2019)

Validation and Evaluation of Antimicrobial Orders Indication for Use
por: Wang, Nan, et al.
Publicado: (2017)

602. Clinical Outcomes of Ertapenem in Patients with Hypoalbuminemia
por: Gavaghan, Victoria, et al.
Publicado: (2022)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

217. Combination Salvage Therapy with Cefazolin Plus Ertapenem for Refractory Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Rose Ulloa, Erlinda, et al.
Publicado: (2019)

2786. Characterizing Ertapenem Neurotoxicity: A Systematic Review
por: Mitaka, Hayato, et al.
Publicado: (2023)

Ceftazidime-avibactam and Meropenem Double Disk Diffusion Test for Identifying Carbapanem-Resistant Enterobacteriaceae and Distinguishing Between Serine and Metallo-β-Lactamase Producing Organisms
por: Lin, Lynn-Yao, et al.
Publicado: (2017)

Ertapenem Resistance of Escherichia coli
por: Lartigue, Marie-Frédérique, et al.
Publicado: (2007)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

2131. Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2019)

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae
por: Abe, Ryuichiro, et al.
Publicado: (2019)

2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
por: Durante, Amanda, et al.
Publicado: (2018)

2266. Persistent Inflammation in HIV Patients With Community-Acquired Pneumonia and Its Correlation With Lung Injury
por: Mao, Ruochen, et al.
Publicado: (2018)

1026. Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals
por: Peterson, Nathan, et al.
Publicado: (2019)

Aminoglycoside Susceptibility Agreement between an Automated System and Broth Microdilution for Carbapenem-resistant Enterobacteriaceae
por: Kulengowski, Brandon, et al.
Publicado: (2017)

Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms
por: Mody, Rupal M, et al.
Publicado: (2007)

2443. Searching for the Optimal Treatment Regimen for Metallo-β-Lactamase Producing Enterobacteriaceae: Aztreonam Plus Ceftazidime–Avibactam vs. Aztreonam Plus Meropenem–Vaborbactam
por: Biagi, Mark, et al.
Publicado: (2018)

2294. Comparative Evaluation of Ertapenem and Clindamycin Plus Gentamicin for the Treatment of Postpartum Endometritis
por: Schweiger, Krislyn, et al.
Publicado: (2019)

1102. Ertapenem vs. Nonertapenem Antibiotics in Colorectal Surgery: A Stewardship Opportunity
por: LaDow, Tiffany, et al.
Publicado: (2019)

177. Distinctive Features of Ertapenem Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort Study
por: Adelman, Max W, et al.
Publicado: (2021)

Assessment of the In Vivo Efficacy of Plazomicin (PLZ) Alone or in Combination with Meropenem (MEM) or Tigecycline (TGC) against Enterobacteriaceae (EB) Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent (I+) Murine Septicemia Model
por: Abdelraouf, Kamilia, et al.
Publicado: (2017)

Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation
por: Sanclemente, Gemma, et al.
Publicado: (2019)

1559. Ertapenem Plus Ceftriaxone or Ceftaroline Dual Β-Lactam Combination for Enterococcus faecalis
por: Cusumano, Jaclyn A, et al.
Publicado: (2019)

Ertapenem-Induced Thrombocytosis
por: Docobo, Ramon A, et al.
Publicado: (2017)

Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate
por: Wu, Yue-E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jttpung6a6bm6796d642jpknbr